Filling a Critical Gap in Relapsed Sarcoma Treatment
Filling a Critical Gap in Relapsed Sarcoma Treatment https://pediatricsnationwide.org/wp-content/uploads/2026/02/AdobeStock_201155773-1024x683.jpeg 1024 683 Pam Georgiana https://pediatricsnationwide.org/wp-content/uploads/2023/07/May-2023.jpg
A first-in-sarcoma trial at Nationwide Children’s Hospital tests universal-donor NK cells with chemotherapy to address poor survival rates. The five-year overall survival rate for children and young adults with relapsed bone or soft tissue sarcomas is between 17 and 26%. For Bhuvana A. Setty, MD, pediatric hematologist and oncologist at Nationwide Children’s Hospital, that reality is not acceptable. …